Sustained low hospitalization rates after four years of rotavirus mass vaccination in Austria

Vaccine

Volumn 31, Issue 24, 2013, Pages 2686-2691

  Paulke Korinek, Maria ^a   Kollaritsch, Herwig ^a   Aberle, Stephan W ^b   Zwazl, Ines ^a   Schmidle Loss, Birgit ^a   Vécsei, Andreas ^c   Kundi, Michael ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c ST ANNA CHILDREN S HOSPITAL   (Austria)

Author keywords

Genotype; Herd effect; Rotavirus gastroenteritis; Universal mass vaccination

Indexed keywords

ROTAVIRUS VACCINE;

ADOLESCENT; APATHY; APHASIA; APNEA; ARTICLE; AUSTRIA; BRAIN DISEASE; CHILD; CONVULSION; DEHYDRATION; DYSPNEA; FEVER; GASTROENTERITIS; GENOTYPE; GROUPS BY AGE; HEMIPARESIS; HOSPITALIZATION; HUMAN; INFANT; INFECTION RATE; INFECTION RISK; LARYNX SPASM; MASS IMMUNIZATION; NEWBORN; PETECHIA; POOR CIRCULATION; PRESCHOOL CHILD; PRIORITY JOURNAL; RASH; RISK ASSESSMENT; ROTAVIRUS INFECTION; SCHOOL CHILD; SENTINEL SURVEILLANCE; SIDE EFFECT; SOMNOLENCE; VACCINATION;

AUSTRIA; CHILD; CHILD, PRESCHOOL; FEMALE; GENOTYPE; HOSPITALIZATION; HUMANS; INTUSSUSCEPTION; MALE; MASS VACCINATION; PREVALENCE; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES;

EID: 84878357365     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.04.001     Document Type: Article

References (32)

1. World Health Organization. Diarrheal disease. Fact sheet No. 330; August 2009 [cited 18.12.12]. Available from: http://www.who.int/mediacentre/factsheets/fs330/en/index.html.
2. World Health Organization Update to position paper (December 2009). WER 2009, 51-52(84):533-540.
3. McDermid A., Le Saux N., Grudeski E., Bettinger J.A., Manguiat K., Halperin S.A., et al. Molecular characterization of rotavirus isolates from select Canadian pediatric hospitals. BMC Infect Dis 2012, 12(1):306.
4. Lepage P., Vergison A. Impact of rotavirus vaccines on rotavirus disease. Expert Rev Anti Infect Ther 2012, 10(5):547-561.
5. Lopman B.A., Curns A.T., Yen C., Parashar U.D. Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States. J Infect Dis 2011, 204(7):980-986.
6. Paulke-Korinek M., Kundi M., Rendi-Wagner P., de Martin A., Eder G., Schmidle-Loss B., et al. Herd immunity after two years of the universal mass vaccination program against rotavirus gastroenteritis in Austria. Vaccine 2011, 29(15):2791-2796.
7. Field E.J., Vally H., Grimwood K., Lambert S.B. Pentavalent rotavirus vaccine and prevention of gastroenteritis hospitalizations in Australia. Pediatrics 2010, 126(3):e506-e512.
8. Payne D.C., Staat M.A., Edwards K.M., Szilagyi P.G., Weinberg G.A., Hall C.B., et al. Direct and indirect effects of rotavirus vaccination upon childhood hospitalizations in 3 US counties, 2006-2009. Clin Infect Dis 2011, 53(3):245-253.
9. Richardson V., Parashar U., Patel M. Childhood diarrhea deaths after rotavirus vaccination in Mexico. N Engl J Med 2011, 365(8):772-773.
10. Richardson V., Hernandez-Pichardo J., Quintanar-Solares M., Esparza-Aguilar M., Johnson B., Gomez-Altamirano C.M., et al. Effect of rotavirus vaccination on death from childhood diarrhea in Mexico. N Engl J Med 2010, 362(4):299-305.
11. ®, into the National Immunization Program of Australia. Pediatr Inf Dis J 2011, 30(1):S48-S53.
12. ® vaccine in Rio de Janeiro, Brazil. Water Res 2011, 45(17):5755-5763.
13. Hull J.J., Teel E.N., Kerin T.K., Freeman M.M., Esona M.D., Gentsch J.R., et al. United States rotavirus strain surveillance from 2005 to 2008: genotype prevalence before and after vaccine introduction. Pediatr Infect Dis J 2011, 30(1 (Suppl.)):S42-S47.
14. Paulke-Korinek M., Rendi-Wagner P., Kundi M., Kronik R., Kollaritsch H. Universal mass vaccination against rotavirus gastroenteritis: impact on hospitalization rates in Austrian children. Pediatr Infect Dis J 2010, 29(4):319-323.
15. Rendi-Wagner P., Kundi M., Mikolasek A., Mutz I., Zwiauer K., Wiedermann U., et al. Active hospital-based surveillance of rotavirus diarrhea in Austrian children, period 1997 to 2003. Wie Klin Wo 2006, 118(9-10):280-285.
16. Gentsch J.R., Glass R.I., Woods P., Gouvea V., Gorziglia M., Flores J., et al. Identification of group A rotavirus gene 4 types by polymerase chain reaction. J Clin Microbiol 1992, 30(6):1365-1373.
17. Das B.K., Gentsch J.R., Cicirello H.G., Woods P.A., Gupta A., Ramachandran M., et al. Characterization of rotavirus strains from newborns in New Delhi, India. J Clin Microbiol 1994, 32(7):1820-1822.
18. Pang X., Cao M., Zhang M., Lee B. Increased sensitivity for various rotavirus genotypes in stool specimens by amending three mismatched nucleotides in the forward primer of a real-time RT-PCR assay. J Virol Methods 2011, 172(1-2):85-87.
19. STATcube, Statistik Austria. Bevölkerung im Jahresdurchschnitt; 2012 [cited: 25.01.13]. Available from: http://sdb.statistik.at/statistik.at/ext/superweb/login.do?guest=guest.
20. Baylis S.A., Finsterbusch T., Bannert N., Bluemel J., Mankertz A. Analysis of porcine circovirus type 1 detected in Rotarix vaccine. Vaccine 2011, 29(4):690-697.
21. Heinz F.X., Holzmann H., Essl A., Kundi M. Field effectiveness of vaccination against tick-borne encephalitis. Vaccine 2007, 25(43):7559-7567.
22. Pitzer V.E., Patel M.M., Lopman B.A., Viboud C., Parashar U.D., Grenfell B.T. Modeling rotavirus strain dynamics in developed countries to understand the potential impact of vaccination on genotype distributions. Proc Natl Acad Sci USA 2011, 108(48):19353-19358.
23. Hanquet G., Ducoffre G., Vergison A., Neels P., Sabbe M., Van Damme P., et al. Impact of rotavirus vaccination on laboratory confirmed cases in Belgium. Vaccine 2011, 29(29-30):4698-4703.
24. Cortese M., Parashar U., Centers for Disease Control and Prevention Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2009, 58(RR-2):1-25.
25. Reichert T.A., Sugaya N., Fedson D.S., Glezen W.P., Simonsen L., Tashiro M. The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med 2001, 344(12):889-896.
26. Ruiz-Palacios G.M., Perez-Schael I., Velazquez F.R., Abate H., Breuer T., Clemens S.C., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006, 354(1):11-22.
27. Dulgheroff A.C.B., Figueiredo E.F., Moreira L.P., Moreira K.C., Moura L.M.S., Gouvea V.S., et al. Distribution of rotavirus genotypes after vaccine introduction in the Triangulo Mineiro region of Brazil: 4-year follow-up study. J Clin Virol 2012, 55(1):67-71.
28. Adlhoch C., Hoehne M., Littmann M., Marques A.M., Lerche A., Dehnert M., et al. Rotavirus vaccine effectiveness and case-control study on risk factors for breakthrough infections in Germany, 2010-2011. Pediatr Infect Dis J 2013, 32(2):e82-e89.
29. Aberle S. Rotavirus: Überwachung zirkulierender Serotypen. Virusepidemiologische Information; 2011; 20. [cited 23.01.13]. Available from: http://www.virologie.meduniwien.ac.at/home/upload/vei/2011/2011.pdf.
30. Iturriza-Gómara M., Dallman T., Bányai K., Böttiger B., Buesa J., Diedrich S., et al. Rotavirus genotypes co-circulating in Europe between 2006 and 2009 as determined by EuroRotaNet, a pan-European collaborative strain surveillance network. Epidemiol Infect 2011, 139(6):895-909.
31. Vesikari T., Matson D.O., Dennehy P., Van Damme P., Santosham M., Rodriguez Z., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006, 354(1):23-33.
32. Vesikari T., Karvonen A., Prymula R., Schuster V., Tejedor J.C., Cohen R., et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007, 370(9601):1757-1763.